SG11202002610TA - Process for the prepration of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives - Google Patents

Process for the prepration of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives

Info

Publication number
SG11202002610TA
SG11202002610TA SG11202002610TA SG11202002610TA SG11202002610TA SG 11202002610T A SG11202002610T A SG 11202002610TA SG 11202002610T A SG11202002610T A SG 11202002610TA SG 11202002610T A SG11202002610T A SG 11202002610TA SG 11202002610T A SG11202002610T A SG 11202002610TA
Authority
SG
Singapore
Prior art keywords
prepration
dimethylimidazo
diazaspiro
octan
pyridazin
Prior art date
Application number
SG11202002610TA
Inventor
Jean-Michel Adam
Serena Maria Fantasia
Daniel Vincent Fishlock
Fabienne Hoffmann-Emery
Gerard Moine
Christophe Pfleger
Christian Moessner
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SG11202002610TA publication Critical patent/SG11202002610TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
    • B01J23/44—Palladium
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/70—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of the iron group metals or copper
    • B01J23/74—Iron group metals
    • B01J23/755—Nickel
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
SG11202002610TA 2017-09-22 2018-09-19 Process for the prepration of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives SG11202002610TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17192711 2017-09-22
PCT/EP2018/075282 WO2019057740A1 (en) 2017-09-22 2018-09-19 Process for the prepration of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives

Publications (1)

Publication Number Publication Date
SG11202002610TA true SG11202002610TA (en) 2020-04-29

Family

ID=59955477

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202002610TA SG11202002610TA (en) 2017-09-22 2018-09-19 Process for the prepration of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives

Country Status (14)

Country Link
US (2) US11390632B2 (en)
EP (1) EP3684766A1 (en)
JP (2) JP7075484B2 (en)
KR (2) KR20230020580A (en)
CN (2) CN111132981B (en)
AR (1) AR112828A1 (en)
AU (1) AU2018337597B2 (en)
BR (1) BR112020005549A2 (en)
CA (1) CA3075968C (en)
IL (1) IL273268B2 (en)
MX (1) MX2020002711A (en)
SG (1) SG11202002610TA (en)
TW (1) TWI812646B (en)
WO (1) WO2019057740A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3684766A1 (en) * 2017-09-22 2020-07-29 H. Hoffnabb-La Roche Ag Process for the prepration of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives
WO2020079203A1 (en) * 2018-10-19 2020-04-23 F. Hoffmann-La Roche Ag New forms of pyrido[1,2-a]pyrimidin-4-one derivatives, its formulation and its process of making
WO2022048675A1 (en) * 2020-09-07 2022-03-10 苏州科睿思制药有限公司 Crystal form of risdiplam, preparation method therefor, and use thereof
WO2022162107A1 (en) 2021-02-01 2022-08-04 Sandoz Ag Crystalline form of risdiplam
CN116981673A (en) 2021-03-17 2023-10-31 豪夫迈·罗氏有限公司 Novel thiadiazolopyrimidinone derivatives
WO2022194801A1 (en) 2021-03-17 2022-09-22 F. Hoffmann-La Roche Ag New thiazolopyrimidinone derivatives
WO2022194909A2 (en) 2021-03-18 2022-09-22 F. Hoffmann-La Roche Ag Novel process
WO2023170115A1 (en) 2022-03-10 2023-09-14 F. Hoffmann-La Roche Ag Pyrido[1,2-a]pyrimidin-4-one derivatives
WO2024003798A1 (en) * 2022-06-29 2024-01-04 Biophore India Pharmaceuticals Pvt. Ltd. A novel process for the preparation of 7 (4, 7- diazaspiro [2.5] octan-7-yl)-2-(2,8 dimethylimidazo[1,2-b] pyrid azin-6- yl) pyrido-4h-[1,2-a] pyrimidin-4-one with novel intermediates
WO2024069646A1 (en) * 2022-09-26 2024-04-04 Natco Pharma Limited Improved process for the preparation of risdiplam and its intermediates

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX352861B (en) 2011-12-30 2017-12-13 Ptc Therapeutics Inc Compounds for treating spinal muscular atrophy.
MX354074B (en) * 2012-02-10 2018-02-12 Ptc Therapeutics Inc Compounds for treating spinal muscular atrophy.
EP3143025B1 (en) 2014-05-15 2019-10-09 F. Hoffmann-La Roche AG Compounds for treating spinal muscular atrophy
CN105111201B (en) * 2014-10-16 2017-01-11 上海页岩科技有限公司 5-methyl-2-(pyridinyl-2-amino)-8H-pyrido[2,3-d]pyrimidin-7-ketone compounds
CA2996657A1 (en) * 2015-11-12 2017-05-18 Kathleen Dorothy MCCARTHY Compounds for treating amyotrophic lateral sclerosis
MX2018005890A (en) * 2015-11-12 2018-08-15 Hoffmann La Roche Compositions for treating spinal muscular atrophy.
EP3684766A1 (en) * 2017-09-22 2020-07-29 H. Hoffnabb-La Roche Ag Process for the prepration of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives

Also Published As

Publication number Publication date
JP2022107003A (en) 2022-07-20
TW201920205A (en) 2019-06-01
JP7398510B2 (en) 2023-12-14
CN116813648A (en) 2023-09-29
IL273268B1 (en) 2023-01-01
WO2019057740A1 (en) 2019-03-28
JP7075484B2 (en) 2022-05-25
MX2020002711A (en) 2020-07-20
US11390632B2 (en) 2022-07-19
US20220324881A1 (en) 2022-10-13
CA3075968A1 (en) 2019-03-28
KR20200058468A (en) 2020-05-27
TWI812646B (en) 2023-08-21
AU2018337597A1 (en) 2020-03-26
CN111132981A (en) 2020-05-08
AR112828A1 (en) 2019-12-18
KR20230020580A (en) 2023-02-10
CN111132981B (en) 2023-10-31
US20200216472A1 (en) 2020-07-09
CA3075968C (en) 2023-04-04
BR112020005549A2 (en) 2020-10-06
EP3684766A1 (en) 2020-07-29
AU2018337597B2 (en) 2021-03-25
IL273268B2 (en) 2023-05-01
IL273268A (en) 2020-04-30
JP2020534330A (en) 2020-11-26

Similar Documents

Publication Publication Date Title
IL273268A (en) Process for the prepration of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives
IL261231B (en) Substituted (r)-4-methyl-3,4-dihydropyrazino[1,2-a]indol-1(2h)-one mcl-1 inhibitors
HK1255028A1 (en) 4-amino-2-(1h-pyrazolo[3,4-b]pyridin-3-yl)-6-oxo-6,7-dihydro-5h-pyrrolo[2,3-d]pyrimidine derivatives and the respective (1h-indazol-3-yl) derivatives as cgmp modulators for treating cardiovascular diseases
RS60261B1 (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
PL3555097T3 (en) Imidazo[4,5-d]pyrrolo[2,3-b]pyridine compounds as inhibitors of janus kinases
EP3546460A4 (en) Pyrimido[5,4-b]indolizine or pyrimido[5,4-b]pyrrolizine compound, preparation method and use thereof
MX2021004487A (en) New forms of pyrido[1,2-a]pyrimidin-4-one derivatives, its formulation and its process of making.
IL270909A (en) Imidazo[1,2-a]pyrazine modulators of the adenosine a2a receptor
EP3543242A4 (en) 8,9-dihydroimidazole[1,2-a]pyrimido[5,4-e]pyrimidine-5(6h)-ketone compound
IL266305B (en) [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors
WO2011156646A3 (en) 6-(sulfonylaryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
ZA201800485B (en) Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy
ZA201904236B (en) Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors
TWI800696B (en) 7-(methylamino)pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives
IL290419A (en) Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors
EP3856743A4 (en) Substituted imidazo [1, 2-a] pyridine and [1, 2, 4] triazolo [1, 5-a] pyridine compounds as ret kinase inhibitors
IL262673A (en) Pyrazolo[1,5-a]pyrimidine compound
IL272988A (en) Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors
IL243269A0 (en) Crystals of (6ar,9as)-5,6a,7,8,9,9a-hexahydro-5-methyl-3-(phenylamino)-2-((4-(6-fluoropyridin-2-yl)phenyl)methyl)-cyclopent[4,5]imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(2h)-one, salts thereof and processes for the manufacture of the salts
EP3475286A4 (en) Substituted pyrrolo [2, 3-d]pyridazin-4-ones and pyrazolo [3, 4-d]pyridazin-4-ones as protein kinase inhibitors
IL281283B1 (en) Improved method for the manufacture of 3-[(1s)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine and polymorphic forms thereof
MX2023004924A (en) New treatment of sma.
MX2018001350A (en) Processes for preparing an fgfr inhibitor.
HK1257427A1 (en) A process for the preparation of 2-pyrazolo[1,5-a]pyrazin-2-ylpyrido[1,2-a]pyrimidin-4-one
ZA202101933B (en) Improved method for the manufacture of 3-[(1s)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine and polymorphic forms thereof